(ESPR)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Esperion Therapeutics, Inc., biofarmatsevtik kompaniya, Qo'shma Shtatlarda yuqori past zichlikdagi lipoprotein xolesterin (LDL-C) darajasi yuqori bo'lgan bemorlarni davolash uchun dori vositalarini ishlab chiqadi va tijoratlashtiradi. Kompaniyaning sotiladigan mahsulotlari orasida NEXLETOL (bempedoik kislota) va NEXLIZET (bempedoik kislota va ezetimib) tabletkalari mavjud bo'lib, ular kattalardagi geterozigot oilaviy giperxolesterinemiya va yurak-qon tomir kasalliklari bo'lgan va LDL-C ni qo'shimcha ravishda kamaytirishni talab qiladigan bemorlarda birlamchi giperlipidemiya uchun kuniga bir marta qabul qilinadigan, og'iz orqali qabul qilinadigan, statin bo'lmagan dori vositalaridir. Uning mahsulotlari orasida NILEMDO, xolesterin biosintezini kamaytirish va LDL retseptorlarini ko'paytirish orqali LDL-C va yurak-qon tomir xavfini kamaytiradigan ATP Sitrat Liyaza (ACL) ingibitori; va yuqori LDL-C ni davolash uchun bempedoik kislota va ezetimib tabletkalari bo'lgan NUSTENDI ham mavjud. Kompaniya Daiichi Sankyo Co. Ltd; Otsuka Pharmaceutical Co., Ltd; va Daiichi Sankyo Europe GmbH bilan litsenziya va hamkorlik shartnomalariga ega. Esperion Therapeutics, Inc. ilgari HDL Therapeutics, Inc. nomi bilan tanilgan va 2008 yil may oyida Esperion Therapeutics, Inc. nomini o'zgartirgan. Kompaniya 2008 yilda ro'yxatga olingan va Ann Arbor, Michigan shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development |
| LeAnne Bloedon M.S. | VP & Head of Development |
| Mr. Benjamin Halladay M.B.A. | Chief Financial Officer |
| Mr. Benjamin O. Looker J.D. | General Counsel & Corporate Secretary |
| Mr. Glenn P. Brame | Chief Technical Operations Officer |
| Mr. John B. Harlow Jr. | Chief Commercial Officer |
| Mr. Sheldon L. Koenig M.B.A. | President, CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-10 | 10-K | espr-20251231.htm |
| 2026-03-03 | 8-K | espr-20260302.htm |
| 2026-01-12 | 8-K | espr-20260111.htm |
| 2025-11-06 | 10-Q | espr-20250930.htm |
| 2025-11-04 | 8-K | espr-20251104.htm |
| 2025-10-08 | 8-K | tm2527818d4_8k.htm |
| 2025-10-07 | 8-K | tm2527818d2_8k.htm |
| 2025-08-13 | S-8 | esprs-882025.htm |
| 2025-08-11 | NT 10-Q | espr06302025nt10-q.htm |
| 2025-08-05 | 8-K | espr-20250805.htm |
| Ms. Betty Jean Swartz |
| Chief Business Officer |
| Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications |